BR9913870A - Método de estimulação da atividade de receptor de prosaposina - Google Patents

Método de estimulação da atividade de receptor de prosaposina

Info

Publication number
BR9913870A
BR9913870A BR9913870-0A BR9913870A BR9913870A BR 9913870 A BR9913870 A BR 9913870A BR 9913870 A BR9913870 A BR 9913870A BR 9913870 A BR9913870 A BR 9913870A
Authority
BR
Brazil
Prior art keywords
prosaposine
receptor activity
stimulation
stimulating
receptor
Prior art date
Application number
BR9913870-0A
Other languages
English (en)
Inventor
S John O'brien
D Elliot Parks
Original Assignee
Myelos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myelos Corp filed Critical Myelos Corp
Publication of BR9913870A publication Critical patent/BR9913870A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MéTODO DE ESTIMULAçãO DA ATIVIDADE DE RECEPTOR DE PROSAPOSINA"<D> Trata-se de um método para estimular a atividade de receptor de prosaposina através da transfecção de células com DNA Ou RNA que codifica a prosaposina ou um agonista de receptor de prosaposina, para a preparação de um medicamento para o tratamento de distúrbios neurodegenerativos ou de distúrbios de mielinização.
BR9913870-0A 1998-09-09 1999-09-09 Método de estimulação da atividade de receptor de prosaposina BR9913870A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14997798A 1998-09-09 1998-09-09
PCT/US1999/020829 WO2000014113A2 (en) 1998-09-09 1999-09-09 Method of stimulating prosaposin receptor activity

Publications (1)

Publication Number Publication Date
BR9913870A true BR9913870A (pt) 2001-07-24

Family

ID=26795763

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913870-0A BR9913870A (pt) 1998-09-09 1999-09-09 Método de estimulação da atividade de receptor de prosaposina

Country Status (9)

Country Link
EP (1) EP1112090A2 (pt)
JP (1) JP2002524468A (pt)
KR (1) KR20010079770A (pt)
AU (1) AU6141599A (pt)
BR (1) BR9913870A (pt)
CA (1) CA2341325A1 (pt)
HK (1) HK1039744A1 (pt)
HU (1) HUP0103994A3 (pt)
WO (1) WO2000014113A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
WO2019070894A1 (en) 2017-10-03 2019-04-11 Prevail Therapeutics, Inc. GENE THERAPIES FOR LYSOSOMIAL DISORDERS
EP3692151A4 (en) 2017-10-03 2021-07-14 Prevail Therapeutics, Inc. GENE THERAPIES FOR LYSOSOMAL DISORDERS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
DE69430824T2 (de) * 1993-08-12 2003-01-23 Neurotech S.A., Evry Biokompatible immunoisolatorische Kapseln, die genetisch veränderte Zellen enthalten
JP2001515866A (ja) * 1997-09-09 2001-09-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プロサポシン受容体アゴニストを利用したアポトーシスの阻害

Also Published As

Publication number Publication date
HUP0103994A2 (hu) 2002-02-28
KR20010079770A (ko) 2001-08-22
HK1039744A1 (zh) 2002-05-10
AU6141599A (en) 2000-03-27
JP2002524468A (ja) 2002-08-06
WO2000014113A2 (en) 2000-03-16
HUP0103994A3 (en) 2004-03-01
EP1112090A2 (en) 2001-07-04
CA2341325A1 (en) 2000-03-16
WO2000014113A3 (en) 2000-11-16

Similar Documents

Publication Publication Date Title
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
FI963294A0 (fi) Naftyyliamidit keskushermostoaineina
GB2353527A (en) Adenosine A 3 receptor modulators
DK0804236T3 (da) Anvendelse af anti-TNF-antistoffer som lægemidler til behandling af sygdomme, som involverer forhøjede interleukin-6-serumniveauer
BR9707366A (pt) Novos aminoácidos ciclicos como agentes farmacéuticos
BR9813028A (pt) Agonistas de prostaglandina e seu uso para tratar distúrbios nos ossos
BR9915744A (pt) Derivados 4-arilquinolin-2-ona 3-substituìdos como moduladores do canal de potássio
EP1382597A3 (en) Steroid receptor modulator compounds and methods
ES2170065T3 (es) Modulacion de la proteina quinasa c por oligonucleotidos.
EP0788307A4 (en) MODULATION BY OLIGONUCLEOTIDES OF THE PROTEIN ASSOCIATED WITH MULTIPLE ANTI-CANCER RESISTANCE
PT1053313E (pt) Oligonucleotidos &#39;&#39;antisense&#39;&#39; optimizados complementares de sequencias de dna metiltransferase
ZA982877B (en) Treatment of central nervous system disorders with selective estrogen receptor modulators.
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
BR0013664A (pt) Composto, uso de um composto, composição farmacêutica, e, métodos para o tratamento de uma doença ou distúrbio associado com agonismo patogênico, agonismo invertido ou antagonismo do receptor de gabaa, para localizar os receptores de gabaa, para inibir a ligação de um composto de benzodiazepina a um receptor de gabaa, e para alterar a atividade de transdução de sinal de receptores gabaa
ATE199829T1 (de) Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon
BR9913870A (pt) Método de estimulação da atividade de receptor de prosaposina
WO2003104397A3 (en) ANTISENSE MODULATION OF PROTEIN KINASE GR 6 EXPRESSION
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
MXPA02001204A (es) Compuestos calciliticos.
ATE230263T1 (de) At1 rezeptor antagonist zur anregung von apoptosis
Hatta et al. Participation of tubulin in the stimulatory regulation of adenylyl cyclase in rat cerebral cortex membranes
ATE256126T1 (de) 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
AU3189199A (en) Antisense modulation of lfa-3
HUP0100105A2 (hu) TNF-antagonisták alkalmazása szeptikus betegségek kezelésére szolgáló gyógyszerként
BR9808066A (pt) Dispositivo e kit para a estimulação da regeneração nervosa, utilização de uma luva biocompatìvel e produto para a liberação local e prolongada de uma substância neurotrófica

Legal Events

Date Code Title Description
PC Transfer

Free format text: MYLS ACQUISITIONS CORP (US)

TC Change of name
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A , 6A E 7A ANUIDADES.